The new report by Expert Market Research titled, ‘Global Bleeding Disorders Therapeutics Market Share, Report and Forecast 2024-2032’, gives an in-depth analysis of the global bleeding disorders therapeutics market, assessing the market based on its segments like disease types, drug classes, and major regions.
The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.
Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/reports/bleeding-disorders-therapeutics-market/requestsample
The key highlights of the report include:
Market Overview (2018-2032)
Forecast CAGR (2024-2032):7.4%
The major factors driving the global market growth include the growing patient population base, research and development activities, and increasing focus on recombinant products by pharmaceutical companies. The increasing focus on developing recombinant factors due to their high efficiency in preventing bleeding episodes over plasma-derived products is driving global market demand. The rising prevalence of liver diseases, anaemia, and other blood coagulation disorders will increase the demand for bleeding disorders treatments. Moreover, the geriatric population are more susceptible to cardiovascular disease, bone fractures, and other illnesses that may necessitate extensive surgical treatments. This is driving up demand for bleeding disorder treatments, which are essential for people with bleeding disorders to avoid excessive bleeding after surgery.
Industry Definition and Major Segments
Bleeding disorders are illnesses that affect the body’s capacity to function properly. White blood cells, red blood cells, platelets, bone marrow, spleen, lymph nodes, and the proteins involved in bleeding and clotting are all affected (hemostasis and thrombosis). The majority of blood problems are caused by gene abnormalities that can be handed down via families.
By disease type, the market is classified into:
Haemophilia A
Haemophilia B
Von Willebrand Disease
Liver Disease
Others
Based on drug class, the market is segmented into:
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Others
On the basis of region, the market is segmented into:
North America
Europe
Asia Pacific
Latin America
Middle East and Afric
Market Trends
The large patient pool and rising expenditure to improve healthcare infrastructure are driving the market growth globally. Haemophilia A is the largest segment based on disease type and is projected to witness healthy CAGR in the forecast period. The growing number of patients suffering from haemophilia A, coupled with increasing awareness and increasing activities for the development of novel products for treating haemophilia A by major pharmaceuticals, are the key drivers for this market growth. Additionally, rising investments in research and development to create treatment options for blood disorders, and the presence of well-established healthcare infrastructure, are driving the entire industry forward.
Key Market Players
The major players in the market are CSL Behring, Bayer AG, Novo Nordisk A/S, Biogen Inc., Sanofi SA, and Octapharma AG, among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.
Related Reports
Clinical Laboratory Services Market: https://www.expertmarketresearch.com/reports/clinical-laboratory-services-market
Companion Animal Vaccine Market: https://www.expertmarketresearch.com/pressrelease/ -companion-animal-vaccine-market
